454 Attributes Decline in Q2 Revenues to Delays from Customers Awaiting GS FLX+ Upgrade | GenomeWeb

By Julia Karow

This article, originally published July 21, has been updated with comments from 454's president and CEO, Chris McLeod.

454 Life Sciences' revenues decreased by an undisclosed amount in the second quarter as sales from Roche's genomic analysis business, which includes 454 and NimbleGen, declined 12 percent during the first half of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.